KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sarepta Therapeutics (SRPT) Assets (2016 - 2025)

Sarepta Therapeutics (SRPT) has 15 years of Assets data on record, last reported at $3.5 billion in Q3 2025.

  • For Q3 2025, Assets fell 2.96% year-over-year to $3.5 billion; the TTM value through Sep 2025 reached $3.5 billion, down 2.96%, while the annual FY2024 figure was $4.0 billion, 21.4% up from the prior year.
  • Assets reached $3.5 billion in Q3 2025 per SRPT's latest filing, down from $3.7 billion in the prior quarter.
  • Across five years, Assets topped out at $4.0 billion in Q4 2024 and bottomed at $2.7 billion in Q3 2021.
  • Average Assets over 5 years is $3.2 billion, with a median of $3.1 billion recorded in 2021.
  • Peak YoY movement for Assets: dropped 6.18% in 2021, then rose 21.4% in 2024.
  • A 5-year view of Assets shows it stood at $3.1 billion in 2021, then dropped by 0.62% to $3.1 billion in 2022, then grew by 4.35% to $3.3 billion in 2023, then rose by 21.4% to $4.0 billion in 2024, then dropped by 11.85% to $3.5 billion in 2025.
  • Per Business Quant database, its latest 3 readings for Assets were $3.5 billion in Q3 2025, $3.7 billion in Q2 2025, and $3.5 billion in Q1 2025.